Biogen stock has delivered a strong 57.2% return over the past year, yet investors are faced with a split verdict on value as a Discounted Cash Flow (DCF) intrinsic value estimate points to a large discount while earnings based multiples screen the shares as expensive. The result is a low overall value score that conflicts with what the DCF suggests.
-
Over the latest 1 year window, Biogen has returned 57.2%, which puts recent share price momentum firmly ahead of its longer term track record.
-
Progress with Alzheimer's treatment LEQEMBI and pipeline assets such as the zorevunersen program for Dravet syndrome can support expectations for future cash flows. In contrast, pressure on the multiple sclerosis franchise and a pricier balance sheet after recent deals may weigh on how much investors are willing to pay for those potential earnings.
-
Biogen scores 2 out of 6 on a broad set of valuation checks , which suggests the stock leans expensive overall even though the DCF intrinsic value estimate indicates it may be undervalued by about 48%.
The issue now is whether Biogen's current share price better reflects the cautious message from the wider valuation checks or the more optimistic intrinsic value estimate from the Discounted Cash Flow (DCF) model.
Scan beyond Biogen and evaluate other stocks that combine strong cash flow support with valuation tension through the 54 high quality undervalued stocks .
Does Biogen Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model looks at the cash Biogen can generate for shareholders over time and discounts it back to today. For Biogen, the latest twelve month free cash flow sits at about $2.6b, and the model assumes that cash flows continue to grow from this base rather than surge or shrink dramatically.
On those assumptions, the DCF points to an estimated intrinsic value of about $425 per share, which implies Biogen stock is roughly 47.6% undervalued compared with the current market price. Recent news around LEQEMBI and the zorevunersen program is cited in the model as support for ongoing cash generation, while the current market price is interpreted as reflecting meaningful uncertainty about how those therapies might translate into lasting free cash flow.
On balance, the Discounted Cash Flow (DCF) work suggests Biogen currently screens as undervalued relative to the cash it is expected to produce.
Our Discounted Cash Flow (DCF) analysis suggests Biogen is undervalued by 47.6%. Track this in your watchlist or portfolio , or discover 54 more high quality undervalued stocks .
Has Biogen Run Too Far on Earnings?
P/E is often the cleanest way to compare Biogen with other profitable biotechs because it links the share price directly to reported earnings. On this basis, Biogen currently trades on a P/E of about 39.4x, which is well above the broader biotech industry average of 17.3x and also above the peer group average of 24.5x.
The fair P/E ratio implied by the broader checks is about 29.3x, so the current 39.4x level represents a clear premium to what the model suggests would be reasonable given Biogen's profile. That premium sits alongside the mixed picture in the underlying business, with newer therapies such as LEQEMBI and zorevunersen offset by pressure in the multiple sclerosis portfolio and a more expensive balance sheet after recent deals.
On earnings based multiples, Biogen stock currently appears overvalued compared with both tailored and industry benchmarks.
See what the numbers say about this price — find out in our valuation breakdown.
The Biogen Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for Biogen pick up where this valuation puzzle leaves off by spelling out which specific assumptions about Biogen's future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Each narrative links its number to a clear view of how growth, profitability and risks might evolve, which you can revisit as new information about Biogen arrives.
The community is split on Biogen, with one camp leaning into late stage neurology upside and the other focused on pricing and pipeline risks.
Bull case: 24% undervalued
"Analysts broadly agree LEQEMBI's rollout will drive revenue, but the scale and pace of adoption are likely meaningfully understated as blood-based biomarker testing, subcutaneous formulations, and direct-to-consumer campaigns radically accelerate eligible patient identification and treatment…"
Read the full Bull Case to see why Biogen could be undervalued
Bear case: 23% overvalued
"Increasing drug pricing scrutiny and global healthcare cost containment efforts are expected to significantly constrain Biogen's ability to achieve or sustain premium pricing on new and existing therapies, directly undermining revenue growth and net margins as payers grow more resistant to high-cost neurodegenerative disease treatments…"
Read the full Bear Case to see why Biogen could be overvalued
Do you think there's more to the story for Biogen? Head over to our Community to see what others are saying!
The Bottom Line
Biogen's Discounted Cash Flow (DCF) intrinsic value estimate points to a significant discount, while the earnings based multiples still flag the stock as overvalued relative to peers. The low overall value score underlines that the broader checks are not yet lining up with the intrinsic value signal. What really decides it from here is whether Biogen can convert its current pipeline and neurology focus into durable cash flows that justify both the DCF optimism and today's premium multiples. The key question for investors is whether the apparent discount reflects mispricing or a fair warning about execution and pricing risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BIIB .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
